drug

Saxenda

Marketedupdated 2mo ago

by Novo Nordisk Inc

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 26 investigational indications.

indications

investigational

Obesity

all catalysts(32)

approval · 32

view all 32 catalysts →

News(0)

no news has mentioned this drug yet

brand

Saxenda

generic

liraglutide

MOA

12.1 Mechanism of Action Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying. GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP.

indication

Obesity

phase

marketed

Saxenda

indications

all catalysts(32)

News(0)

Report a data issue

Patent cliff

patents (8)

FDA exclusivities (1)

comments(0)

🐶 often sniffed alongside

Trials studying Saxenda